Monopar Therapeutics

Monopar Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. engages in building a drug development pipeline through the licensing and acquisition of oncology therapeutics in late preclinical and clinical development stages. Its product pipeline includes Validive, Camsirubicin and MNPR-101. The company was founded by Chandler D. Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Monopar Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing proprietary therapeutics for cancer patients. It also focuses on building a drug development pipeline through the licensing, and acquisition of therapeutics in late preclinical and clinical development stages. The company was founded by Chandler Drew Robinson, Christopher M. Starr and Andrew P. Mazar in December 2014 and is headquartered in Wilmette, IL.

WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering, Monopar announced the concurrent pricing of a private placement of pre-funded warrants to purchase 882,761 shares of common stock at a purchase price of $23.789 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Monopar from the registered offering and private placement, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $40 million. The offering is expected to close on or about December 23, 2024, subject to customary closing conditions.

Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants

WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar's antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.

Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu

WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference.

Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference

MicroStrategy Incorporated

Sezzle Inc

Investors favoring a short horizon and possessing a fair amount of risk tolerance sometimes look to stocks that have already been trending upward in an effort to capitalize on their momentum. This investment strategy often looks more toward price movement than it does the fundamentals of a company.

3 Momentum Stocks Soaring Into 2025 and Beyond

Monopar Therapeutics (MNPR) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed through our shorter-term trading strategy-based screen.

What Makes Monopar Therapeutics (MNPR) a Good Fit for 'Trend Investing'

Monopar Therapeutics is a clinical-stage biotech focused on radiopharmaceuticals for oncology and recently expanded into rare diseases with ALXN-1840. MNPR's oncology pipeline includes MNPR-101-Zr for diagnostics and MNPR-101-Lu/Ac for therapeutic applications, both in the early development stages. ALXN-1840, a Phase 3 asset for Wilson disease, diversifies MNPR's portfolio but does not directly complement its oncology focus.

Monopar Therapeutics: Radiopharmaceuticals And Rare Disease Potential In Focus

In-licensed ALXN-1840 (a Late-Stage Wilson Disease Drug Candidate) from Alexion, AstraZeneca Rare Disease Two Novel Radiopharma Clinical Trials now Active and Enrolling Patients with Advanced Solid Cancers

Monopar Therapeutics Reports Third Quarter 2024 Financial Results and Recent Developments

WILMETTE, Ill., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the closing of its previously announced best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company.

Monopar Therapeutics Inc. Announces Closing of $19.2 Million Public Offering of Common Stock

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of its best efforts public offering of shares of its common stock at a public offering price of $16.25 per share, for aggregate gross proceeds of approximately $19.2 million, before deducting the placement agent's fees and other offering expenses payable by the Company. The offering is expected to close on October 30, 2024, subject to satisfaction of customary closing conditions.

Monopar Therapeutics Inc. Announces Pricing of $19.2 Million Public Offering of Common Stock

WILMETTE, Ill., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar Therapeutics” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that it intends to offer to sell shares of its common stock in a best efforts public offering. All of the shares of common stock are to be sold by the Company. The offering is subject to market conditions and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.

Monopar Therapeutics Inc. Announces Proposed Public Offering of Common Stock

The stock price of Monopar Therapeutics (NASDAQ: MNPR), a clinical-stage biopharmaceutical company, skyrocketed from levels of $5.25 on Monday, October 21, to $32.66 on Thursday, October 24, before falling to around $17 now. The 6x rise in a matter of days can be attributed to a major licensing development for Monopar.

Up 600% Then Down 50% In 2 Days: What Is Going On With MNPR Stock?

Monopar Therapeutics NASDAQ: MNPR saw its stock skyrocket over 400% on Thursday after announcing a licensing deal with AstraZeneca. By 2 PM, the stock had traded over 10 million shares, far above its usual daily volume of 800,000.

Monopar Therapeutics Skyrockets 400% on Licensing Deal

AstraZeneca

Monopar Therapeutics Inc. MNPR stock is skyrocketing on Thursday.

Monopar Therapeutics Stock Jumps 4X, Inks Licensing Pact With AstraZeneca For Once Terminated Phase 3 Candidate For Rare Genetic Disorder

WILMETTE, Ill., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the clinical and preclinical development of its novel first-in-class lead radiopharma program based on MNPR-101 at the European Association of Nuclear Medicine (EANM) 2024 Annual Congress held in Hamburg, Germany. MNPR-101-Lu radiation dosimetry analytics using human data from MNPR-101-Zr show a favorable organ safety profile at high Lu-177 therapeutic dose levels. The slides for Monopar's oral presentation can be found at the following link: https://www.monopartx.com/pipeline/mnpr-101/eanm24-ppt.

Monopar Presents Encouraging Human Clinical Dosimetry Data on its uPAR Program at EANM 2024

WILMETTE, Ill., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the filing of a provisional patent covering new therapeutic radiopharmaceuticals based on a family of linkers used to connect radioisotopes with targeting agents, including Monopar's uPAR targeting antibody MNPR-101.

Monopar Expands Radiopharma Intellectual Property Portfolio with Patent Filing on New Compounds and Linkers

WILMETTE, Ill., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced positive early data from its ongoing open-label MNPR-101-Zr Phase 1 imaging and dosimetry clinical trial confirming MNPR-101-Zr's tumor targeting ability in humans.

Monopar Announces Positive Early Human Clinical Data Validating the Tumor Targeting Ability of MNPR-101-Zr

WILMETTE, Ill., Aug. 27, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it received notice from The Nasdaq Stock Market LLC (Nasdaq) that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) as a result of the closing bid price of the Company's common stock being $1.00 per share or greater for 10 consecutive trading sessions. The Company is now compliant with the minimum bid price listing standard for continued Nasdaq listing.

Monopar Regains Compliance with Nasdaq Minimum Bid Price Rule

WILMETTE, Ill., Aug. 21, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced it has received Human Research Ethics Committee (HREC) clearance in Australia to commence a Phase 1 therapeutic trial of its novel radiopharmaceutical MNPR-101-Lu.

Monopar Receives Clearance to Proceed with Phase 1 Therapeutic Trial of Novel Radiopharmaceutical in Advanced Cancers

WILMETTE, Ill., Aug. 14, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced the successful dosing of the first patient in its open-label Phase 1 imaging and dosimetry clinical trial of its uPAR-targeted imaging radiopharmaceutical MNPR-101-Zr.

Monopar Announces Initial Data for First Patient Dosed in Radiopharma Phase 1 Clinical Trial of MNPR-101-Zr

WILMETTE, Ill., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that it will effect a 1-for-5 reverse stock split of its outstanding shares of common stock (the “Reverse Stock Split”). The Company expects that the Reverse Stock Split will become effective at 5:00 pm on Monday August 12, 2024, and its common stock will begin trading on a split-adjusted basis at the open of trading on Tuesday, August 13, 2024 under the new CUSIP number 61023L207. Monopar's common stock will continue to trade on the NASDAQ Capital Market under the symbol “MNPR”. The Reverse Stock Split is an effort to regain compliance with Nasdaq's listing rules.

Monopar Therapeutics Announces 1-for-5 Reverse Stock Split

Initiated and Enrolling Patients into MNPR-101-Zr First-in-Human Phase 1 Radiopharma Clinical Trial MNPR-101 radio-immuno-therapeutic (RIT) Clinical Trial on Track to Initiate in Q4 2024

Monopar Therapeutics Reports Second Quarter 2024 Financial Results and Recent Developments

WILMETTE, Ill., June 25, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharma company focused on developing innovative treatments for cancer patients, today announced that its abstract titled “Evaluation of Anti-uPAR Antibody as a Radiopharmaceutical for Imaging and Treatment of Solid Tumors” has been accepted as a “Top-Rated Oral Presentation” within the Scientific Program of the European Association of Nuclear Medicine (EANM) 2024 Annual Congress to be held on October 19-23, 2024 in Hamburg, Germany.

Monopar Announces MNPR-101-RIT Abstract Accepted as a Top-Rated Oral Presentation at EANM'24

Highlights: Builds on Companies' respective core strengths Aligns intellectual property rights Establishes a long-term supply agreement under which NorthStar provides actinium-225 for Monopar's development and potential future commercial programs WILMETTE, Ill. and Beloit, Wis.

Monopar and NorthStar Amend & Extend Collaboration

WILMETTE, Ill., June 10, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage radiopharmaceutical company focused on developing innovative treatments for cancer patients, is presenting today data from the preclinical development of its novel first-in-class lead radiopharma program MNPR-101-Zr at the 2024 Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting in Toronto, Canada. SNMMI is the premier educational, scientific, and research event in the radiopharma space. Monopar's poster presentation can be found at the following link: https://www.monopartx.com/pipeline/mnpr-101/snmmi-poster-june-2024.

Monopar Presents Data Showcasing the Appeal of uPAR as a Radiopharma Cancer Target and of its lead Clinical Program at the 2024 SNMMI Annual Meeting

Aurora Innovation

Petco Health and Wellness

Penny stocks are risky. That's why we attach a warning to the tail-end of penny stock articles.

News for Monopar Therapeutics Stock (MNPR)